Rates and predictors of HBsAg loss after discontinuation of effective
long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative
chronic hepatitis B patients: Results from the DARING-B prospective
Greek study
Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2018
Συγγραφείς:
Papatheodoridis, M. Rigopoulou, E. Hadziyannis, E. Kalliopi, Z. Xourafas, V. Lyberopoulou, A. Gatselis, N. and Vlachogiannakos, I. Manolakopoulos, S. Dalekos, G. and Papatheodoridis, G.